Théa won’t buy ProQR’s ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in October

ProQR’s failed divestiture: Laboratoires Théa scrapped plans to buy ProQR Therapeutics’ late-stage ophthalmic pipeline after announcing a deal in early August for €147.5 million, or about $162 million. On Wednesday, ProQR said some of its ophthalmology workers decided not to join the new company, and as a result, Théa terminated the deal. — Jaimy Lee

Immunovant’s $130 million offering: Immunovant’s early-stage autoimmune data, viewed by analysts as a potential catalyst for a sale or other transaction, spurred a major financing haul for the New York biotech. It presented data on its anti-FcRn IMVT-1402 Tuesday morning. Later that day, it disclosed plans for a $130 million public offering and a $170 million boost from its parent, Roivant Sciences. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Early data are promising for autoimmune disease drug from Roivant Sciences’s Immunovant

Results released Tuesday from an early study of an autoimmune disease drug from Roivant Sciences’s Immunovant showed the treatment could reduce the levels of a

September 26, 2023

FDA seizes thousands of counterfeit Ozempic units, warns consumers not to use

The FDA is warning consumers not to use counterfeit Ozempic after it found thousands of units of fake product in the supply chain. The agency

December 29, 2023

Pulmonary Embolism During COVID Infection a Deadly Mix

HONOLULU — During the first year of the pandemic, patients with pulmonary embolism (PE) had higher in-hospital mortality rates when they also had concomitant COVID-19,

October 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.